Abstract
A targeted radiotherapy/gene therapy approach for prostate cancer, using the radiopharmaceutical [131I]meta-iodobenzylguanidine ([131I]MIBG), would restrict the effects of radiotherapy to malignant cells, thereby increasing efficacy and decreasing morbidity of radiotherapy. Prostate cancer cells were transfected with a transgene encoding the noradrenaline transporter (NAT) under the control of tumour-specific telomerase promoters, enabling them to actively take up [131I]MIBG. This led to tumour-specific cell kill. This strategy has the advantage of generating a radiological bystander effect, leading to the destruction of neighbouring tumour cells that have escaped transfection. This targeted approach could be a promising tumour-specific treatment option for prostate cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 355-363 |
| Number of pages | 9 |
| Journal | Prostate Cancer and Prostatic Diseases |
| Volume | 7 |
| Issue number | 4 |
| Early online date | 12 Oct 2004 |
| DOIs | |
| Publication status | Published - 1 Dec 2004 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- [I]MIBG
- bystander effect
- gene therapy
- targeted radiotherapy
- telomerase
Fingerprint
Dive into the research topics of 'Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver